PAVM vs MGRX

For growth investors, PAVmed Inc.

(PAVM) is the stronger pick with 22. 1% revenue growth year-over-year, versus -15. 8% for Mangoceuticals, Inc. (MGRX). PAVmed Inc. (PAVM) offers the better valuation at 14. 4x trailing P/E, making it the more compelling value choice. Analysts rate PAVmed Inc. (PAVM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, PAVmed Inc.

(PAVM) delivered a total return of -89. 1%, compared to -99. 4% for Mangoceuticals, Inc. (MGRX). Over 10 years, the gap is even starker: PAVM returned -90. 5% versus MGRX's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mangoceuticals, Inc.

(MGRX) is the lower-risk stock at 0. 90β versus PAVmed Inc. 's 1. 86β — meaning PAVM is approximately 106% more volatile than MGRX relative to the S&P 500.

By revenue growth (latest reported year), PAVmed Inc.

(PAVM) is pulling ahead at 22. 1% versus -15. 8% for Mangoceuticals, Inc. (MGRX). On earnings-per-share growth, the picture is similar: PAVmed Inc. grew EPS 105. 4% year-over-year, compared to 48. 7% for Mangoceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PAVmed Inc.

(PAVM) is the more profitable company, earning 1329% net margin versus -1413. 6% for Mangoceuticals, Inc. — meaning it keeps 1329% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MGRX leads at -1294. 4% versus -1485. 4% for PAVM. At the gross margin level — before operating expenses — MGRX leads at 61. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, MGRX (100.

0% yield) pays a dividend. PAVM does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Mangoceuticals, Inc.

(MGRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 100. 0% yield). PAVmed Inc. (PAVM) carries a higher beta of 1. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MGRX: -99. 4%, PAVM: -90. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PAVM is a small-cap high-growth stock; MGRX is a small-cap income-oriented stock. MGRX pays a dividend while PAVM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.